OncoKB New Data Release - March 28, 2025
Contact OncoKB
Data Release v4.27
March 28, 2025
What's New
Updated Therapeutic Implications:
New alteration(s) with a tumor type-specific level of evidence
Level 4: ERBB2 Oncogenic Mutations in biliary tract cancer based on anecdotal clinical data of response to Neratinib, Trastuzumab Deruxtecan and Pertuzumab + Trastuzumab in patients with ERBB2 mutant biliary tract cancer (PMID: 36746967, 38710187, 38748939)
Promotion of tumor type-specific level of evidence for an alteration
Level 2: ERBB2 Oncogenic Mutations in breast cancer promoted from Level 3A to Level 2 based on Breast Cancer NCCN Guideline V3.2025 inclusion of Neratinib + Trastuzumab + Fulvestrant for patients with ERBB2 mutant breast cancer (PMID: 37597578)
Level 3A sensitivity-associated evidence currently in OncoKB™ for ERBB2 Oncogenic Mutations in breast cancer: Neratinib
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Mirdametinib to NF1 Oncogenic Mutations in neurofibroma based on FDA approval of mirdametinib for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection (PMID: 39514826)
Level 1 sensitivity-associated evidence currently in OncoKB™ for NF1 Oncogenic Mutations in neurofibroma: Selumentinib
Gene Curation:
Addition of 5 new genes:
DIS3L2 ERCC6 FANCB MTHFR NFATC2
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
